These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 34379359)

  • 1. Device interaction between cardiac contractility modulation (CCM) and subcutaneous defibrillator (S-ICD).
    Trolese L; Faber T; Gressler A; Steinfurt J; Stuplich J; Jordan E; Bode C; Zehender M; Hilgendorf I
    J Cardiovasc Electrophysiol; 2021 Nov; 32(11):3095-3098. PubMed ID: 34379359
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of combined cardiac contractility modulation and subcutaneous defibrillator therapy in patients with heart failure and reduced ejection fraction.
    Röger S; Rudic B; Akin I; Shchetynska-Marinova T; Fastenrath F; Tülümen E; Liebe V; El-Battrawy I; Baumann S; Kuschyk J; Borggrefe M
    Clin Cardiol; 2018 Apr; 41(4):518-524. PubMed ID: 29697870
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subcutaneous implantable cardioverter-defibrillator: First single-center experience with other cardiac implantable electronic devices.
    Kuschyk J; Stach K; Tülümen E; Rudic B; Liebe V; Schimpf R; Borggrefe M; Röger S
    Heart Rhythm; 2015 Nov; 12(11):2230-8. PubMed ID: 26073595
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardiac contractility modulation and subcutaneous defibrillator (S-ICD): First experience with simultaneous implantation.
    Yao J; Gao J; Yan JF; Fang S
    Pacing Clin Electrophysiol; 2023 Dec; 46(12):1595-1598. PubMed ID: 36938703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heart Failure With Reduced Ejection Fraction And A Narrow QRS Complex: Combination Of A Subcutaneous Defibrillator With Cardiac Contractility Modulation.
    Röger S; Borggrefe M; Kuschyk J
    J Atr Fibrillation; 2015; 8(3):1081. PubMed ID: 27957197
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of an electrocardiographic screening tool to determine candidacy for a subcutaneous implantable cardioverter-defibrillator.
    Groh CA; Sharma S; Pelchovitz DJ; Bhave PD; Rhyner J; Verma N; Arora R; Chicos AB; Kim SS; Lin AC; Passman RS; Knight BP
    Heart Rhythm; 2014 Aug; 11(8):1361-6. PubMed ID: 24755323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of myopotential induction in subcutaneous implantable cardioverter-defibrillator patients: Is the oversensing issue really solved?
    van den Bruck JH; Sultan A; Plenge T; Seuthe K; Mödder T; Iliadis C; Stern D; Blankenheim T; Steven D; Lüker J
    Heart Rhythm; 2019 Oct; 16(10):1523-1530. PubMed ID: 31048064
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inappropriate subcutaneous implantable cardioverter-defibrillator shocks due to T-wave oversensing can be prevented: implications for management.
    Kooiman KM; Knops RE; Olde Nordkamp L; Wilde AA; de Groot JR
    Heart Rhythm; 2014 Mar; 11(3):426-34. PubMed ID: 24321235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of exercise electrocardiogram to screen for T-wave oversensing after implantation of subcutaneous implantable cardioverter-defibrillator.
    Afzal MR; Evenson C; Badin A; Patel D; Godara H; Essandoh M; Okabe T; Tyler J; Houmsse M; Augostini R; Hummel J; Kalbfleisch S; Daoud EG; Weiss R
    Heart Rhythm; 2017 Oct; 14(10):1436-1439. PubMed ID: 28624663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility of Pacemaker Patients for Subcutaneous Implantable Cardioverter Defibrillators.
    Ip JE; Wu MS; Kennel PJ; Thomas G; Liu CF; Cheung JW; Markowitz SM; Lerman BB
    J Cardiovasc Electrophysiol; 2017 May; 28(5):544-548. PubMed ID: 28185354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Device-device interaction].
    Johnson V; Hamm CW; Schmitt J
    Herzschrittmacherther Elektrophysiol; 2019 Jun; 30(2):183-190. PubMed ID: 30989336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous Implantable Cardioverter Defibrillator Lead Repositioning for Preventing Inappropriate Shocks Due to Myopotential Oversensing in a Post-Fulminant Myocarditis Patient.
    Sasaki T; Nakamura K; Naito S
    Int Heart J; 2019 Mar; 60(2):466-469. PubMed ID: 30745542
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two-incision technique for implantation of the subcutaneous implantable cardioverter-defibrillator.
    Knops RE; Olde Nordkamp LR; de Groot JR; Wilde AA
    Heart Rhythm; 2013 Aug; 10(8):1240-3. PubMed ID: 23707489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous Implantable Cardioverter Defibrillator in Patients With Hypertrophic Cardiomyopathy: An Initial Experience.
    Weinstock J; Bader YH; Maron MS; Rowin EJ; Link MS
    J Am Heart Assoc; 2016 Feb; 5(2):. PubMed ID: 26873684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiac contractility modulation: first experience in heart failure patients with reduced ejection fraction and permanent atrial fibrillation.
    Röger S; Schneider R; Rudic B; Liebe V; Stach K; Schimpf R; Borggrefe M; Kuschyk J
    Europace; 2014 Aug; 16(8):1205-9. PubMed ID: 24706089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Which patients are not suitable for a subcutaneous ICD: incidence and predictors of failed QRS-T-wave morphology screening.
    Olde Nordkamp LRA; Warnaars JLF; Kooiman KM; de Groot JR; Rosenmöller BRAM; Wilde AAM; Knops RE
    J Cardiovasc Electrophysiol; 2014 May; 25(5):494-499. PubMed ID: 24320684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Peri-procedural routines, implantation techniques, and procedure-related complications in patients undergoing implantation of subcutaneous or transvenous automatic cardioverter-defibrillators: results of the European Snapshot Survey on S-ICD Implantation (ESSS-SICDI).
    Lenarczyk R; Boveda S; Haugaa KH; Potpara TS; Syska P; Jedrzejczyk-Patej E; Chauvin M; Sadoul N; Dagres N
    Europace; 2018 Jul; 20(7):1218-1224. PubMed ID: 29762683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined leadless pacemaker and subcutaneous implantable defibrillator therapy: feasibility, safety, and performance.
    Tjong FV; Brouwer TF; Smeding L; Kooiman KM; de Groot JR; Ligon D; Sanghera R; Schalij MJ; Wilde AA; Knops RE
    Europace; 2016 Nov; 18(11):1740-1747. PubMed ID: 26941338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.
    Nazer B; Dale Z; Carrassa G; Reza N; Ustunkaya T; Papoutsidakis N; Gray A; Howell SJ; Elman MR; Pieragnoli P; Ricciardi G; Jacoby D; Frankel DS; Owens A; Olivotto I; Heitner SB
    Heart Rhythm; 2020 Jul; 17(7):1107-1114. PubMed ID: 32084597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electromagnetic interference from left ventricular assist devices in patients with subcutaneous implantable cardioverter-defibrillators.
    Ishida Y; Payne JE; Field ME; Gold MR
    J Cardiovasc Electrophysiol; 2020 May; 31(5):1195-1201. PubMed ID: 32128931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.